A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of CHF10136, Administered Via Dry Powder Inhaler, After Single Ascending Dose in Healthy Subjects, Multiple Ascending Doses in Mild Asthmatic Subjects and Followed by a Repeated Dose in One Cohort of Moderate-to-Severe Asthmatic Subjects
This study evaluates the safety and tolerability of CHF10136 administered by inhalation in healthy adults and adults with asthma. The study includes single-dose, multiple-dose, and repeated-dose treatment periods and will also characterize the pharmacokinetic profile of CHF10136.
⁃ For PART 1 - SAD
• Healthy male or female participant ≥18 and ≤55 years of age
• Body mass index (BMI) ≥18 and ≤30 kg/m2 at screening and weight at least 50 kg;
• Good physical and mental status, determined via assessment of medical history at screening and physical examination at screening and prior to randomisation;
• Spirometry measurements within normal limits at screening and prior to randomisation based on the American Thoracic Society (ATS)/European Respiratory Society (ERS) interpretative strategies for spirometry. The forced expiratory volume in the first second (FEV1) must be \>80% of predicted normal value and the FEV1/Forced Vital Capacity (FVC) ratio must be \>0.7.
• Male and Female participants willing and able to comply with study procedures
⁃ For PART 2 - MAD
• Male or female participants ≥18 and ≤55 years of age at screening
• BMI ≥18 and ≤32 kg/m2 at screening and weight at least 50 kg;
• Physician-diagnosed asthma for at least 6 months and before the age of 50 years. Documented evidence of one of the confirmed variable expiratory airflow criteria, as per the GINA 2026 guidelines, is required within 10 years prior to screening.
• Not currently receiving regular maintenance therapy for asthma, with no changes to treatment within \<4 weeks prior to screening, and no exposure to ICS in the 12 weeks prior to screening including ICS reliever therapy;
• Pre-bronchodilator FEV1 ≥70% of predicted at the screening visit and prior to randomisation;
• Male and Female participants willing and able to comply with study procedures
⁃ For PART 3 - REPEATED DOSE
• Male or female participants ≥18 and ≤65 years of age at screening
• BMI ≥18 and ≤35 kg/m2 at screening and weight at least 50 kg;
• Physician-diagnosed asthma for at least 6 months and before the age of 50 years. Documented evidence of one of the confirmed variable expiratory airflow criteria, as per the GINA 2026 guidelines, is required within 10 years prior to screening.
• On a stable asthma treatment regimen of medium to high dose Inhaled Corticosteroids/Long-Acting Beta2-Agonists(ICS/LABA) (as defined by GINA 2026 guidelines) with no changes to treatment within 12 weeks prior to screening.
• Pre-bronchodilator FEV1 ≥40% and ≤90% of predicted at the screening visit and prior to randomisation;
• Asthma Control Questionnaire - 6 Items (ACQ-6) score of 0.5 to 3.0 at screening and prior to randomisation;
• Male and Female participants willing and able to comply with study procedures